Table 3.

OR (95% CI) of localized and advanced prostate cancer by thirds of serum IGF-I and IGFBP-3 concentrations in EPIC

Localized*
Advanced
Pheterogeneity
No. cases/controlsOR (95% CI)No. cases/controlsOR (95% CI)
IGF-I
    Low87/1021.0037/491.00
    Medium122/981.48 (0.98-2.23)51/471.47 (0.81-2.66)
    High94/1031.11 (0.71-1.73)50/421.65 (0.88-3.08)
    Ptrend0.480.210.53
Residuals of IGF-I after adjusting for IGFBP-3
    Low87/1021.0037/491.00
    Medium122/981.25 (0.81-1.93)51/471.21 (0.68-2.16)
    High94/1031.30 (0.84-2.01)50/421.76 (0.92-3.40)
    Ptrend0.640.110.26
IGFBP-3
    Low99/1011.0042/501.00
    Medium102/1080.98 (0.65-1.47)44/321.52 (0.86-2.70)
    High102/941.13 (0.73-1.76)52/561.10 (0.63-1.93)
    Ptrend0.620.860.88
Residuals of IGFBP-3 after adjusting for IGF-I
    Low111/1151.0045/391.00
    Medium94/931.06 (0.70-1.58)46/440.84 (0.44-1.62)
    High98/951.09 (0.71-1.66)47/550.68 (0.35-1.33)
    Ptrend0.930.390.44
  • * Based on 303 case-control pairs where the case was diagnosed with localized disease (tumor-node-metastasis staging score of T1-T2 and N0 and M0, or equivalent).

  • Based on 138 case-control pairs where the case was diagnosed with advanced disease (T3/T4 and/or N1:N3 and/or M1, or equivalent).

  • Ptrend based on the continuous (log transformed) variable.